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Any ?brotic condition can be the subject of the invention,

WITHANOLIDE COMPOUNDS AS
INHIBITORS OF FIBROSIS AND
IDENTIFICATION OF MOLECULAR
TARGETS FOR ANTI-FIBROTIC DRUG
DEVELOPMENT

such as the ?brosis that is associated With organ failure in a

variety of chronic diseases affecting the lungs, kidney, eyes,
heart, liver and skin. Such ?brotic conditions include diabetic

nephropathy, glomerulosclerosis, IgA nephropathy, diabetic
retinopathy, advanced macular degeneration, liver cirrhosis

CROSS-REFERENCE TO RELATED
APPLICATIONS

and biliary atresia, congestive heart failure, endomyocardial
?brosis, idiopathic myocardiopathy, lung ?brosis, diffuse
parenchymal lung disease, mediastinal ?brosis, progressive

This application claims priority to US. Provisional Appli
cation No. 60/781,973, ?led Mar. 13, 2006, Which is incor

massive ?brosis, ?brosis of the lungs associated With tuber
culosis, scleroderma, ?brosis associated With cancerous
groWth, endometriosis, ?brosis associated With surgery, alco
hol-related liver damage, cardiovascular disease, and retinal

porated herein in its entirety.
FIELD OF THE INVENTION

detachment.
The present inventors have discovered that in?ammation
and ?brosis are associated With activation of the in?amma

The present invention relates to methods of screening com

pounds for treating ?brosis and to methods for treating ?bro
sis.

tory transcription factor NF-kappa-B, a key mediator of
cytokine gene activation and immune regulation. Activation

DESCRIPTION OF THE RELATED ART
20

Fibrosis is a deviant process of tissue repair. It is a serious

complication after major surgical procedures and organ trans

(UPP), the principal machinery for intracellular protein deg

plants, and can also occur during cancerous groWth,

endometriosis, alcohol-related liver damage, cardiovascular
disease, retinal detachment, and other disorders. Thus, ?bro
genic complications contribute to the pathogenesis of many

25

radation. Inhibiting the UPP via an appropriate inhibitor is
used according to the present invention to identify com
pounds Which are effective for treating ?brosis. Inhibition of
the UPP is also associated With a reduction in the level of

common and devastating diseases and yet there is no effective
treatment for this chronic problem. Hence, an unaddressed
need exists in the industry to address the aforementioned

ubiquitinated transketolase in the cell. In another embodi
ment, the effect of a test compound on a cell molecule is

de?ciencies and inadequacies.
30

SUMMARY OF THE INVENTION

In one embodiment, the invention provides a method of
screening for a drug effective for treating a ?brotic disease.
The method comprises exposing a cell to a test compound,

of NF-kappa-B occurs in coordination With increases in the

biochemical activities of the ubiquitin proteasome pathWay

35

compared With the effect of a Withanolide compound to deter
mine Whether the test compound is effective for treating a
?brotic disease. Also described is a method of treating ?brosis
via administration of a UPP-inhibitory compound. In one
embodiment, a ?brotic condition is treated by administration
of a Withanolide compound.
The methods of the present invention can be used With any

monitoring the effect of the test compound on the amount or
form of a cell molecule, comparing the amount or form of the

mammalian species, including human, monkey, coW, sheep,
pig, goat, horse, mouse, rat, dog, cat, rabbit, guinea pig,

cell molecule With the result obtained by treatment of the cell

hamster and horse. Humans are preferred.

With an anti-?brotic-effective amount of a Withanolide com

pound, and selecting a drug effective for treating a ?brotic
disease based on the ability of the test compound to provide
the effect obtained by the Withanolide compound on the cell
molecule.
In another embodiment, the invention provides a method of
screening for a drug effective for treating a ?brotic disease.
The method comprising exposing a cell to a test compound,
monitoring the effect of the test compound on the intracellular

In performing screening procedures for identifying UPP
40

can be used according to the present invention. Such screen

ing procedures can be performed in vitro or in vivo. For
example, cells in culture can be exposed to a test compound
45

inhibitory activity.
50

cells, epithelial cells, epidermal cells, keratinocytes, hemato
poietic cells, melanocytes, chondrocytes, lymphocytes (B
55

cells from any organ may be used, e. g., eye, brain, skin, lung,

prising a Withanolide compound Which inhibits intracellular
60

pancreas, liver, stomach, intestine, esophagus, spleen, thy
mus, thyroid gland, salivary gland, bone, heart, skeletal
muscle, reproductive organs, bladder, kidney, urethra and

DESCRIPTION OF PREFERRED
EMBODIMENTS

the treatment of ?brotic conditions.

and T lymphocytes), erythrocytes, macrophages, monocytes,
mononuclear cells, ?broblasts, hepatocytes, cardiac muscle
cells or other muscle cells, or a corneal cell, choroidal cell or
any other cell of the eye, etc. Cells Which can be used include
all somatic or germ cells. Moreover, any mammalian organ or

ing an anti-?brotic effective amount of a Withanolide com

The invention relates generally to methods for treating
?brotic conditions and to procedures for identifying drugs for

Appropriate mammalian cells for use in the screening pro

cedures of the invention include, by Way of example, neural

pound to a mammal in need of treatment for ?brosis. Also
provided is a composition for the treatment of ?brosis com

ubiquitination of transketolase.

for evaluation as to Whether the test compound possesses
UPP-inhibitor activity. In another embodiment, test com
pound canbe administered to a subject, and then cells, a tissue
or an organ can be removed from the subject and then be
evaluated as to Whether the test compound possesses UPP

activity of the ubiquitin proteasome pathWay (UPP), compar
ing the intracellular activity of the UPP With the result
obtained by treatment of the cell With an anti-?brotic-effec
tive amount of a Withanolide compound, and selecting a drug
effective for treating a ?brotic disease based on the ability of
the test compound to provide the effect obtained by the Witha
nolide compound on the UPP.
In yet another embodiment, the invention provides a
method of treating a ?brotic disease comprising administer

inhibitory compounds, any mammalian cell, tissue or organ

65

other urinary organs, etc.
Withanolide compounds are inhibitors of the UPP. Thus, in
evaluating Whether a test compound possesses anti-?brotic
activity, the effect of a test compound can be compared With
the effect of a Withanolide compound.

US 8,283,323 B2
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3
stances present in the plant Wilhania somnifera. Chemically,

cells and lacrimal gland cells. It has been suggested that the
in?ammation transcription factor NF-kappaB plays a role in

Withanolides are steroidal lactones. Exemplary Withanolides

tissue repair by controlling cytokine autocrine loops, i.e.,

Which possess UPP-inhibitory activity include Withaferin A,
Withanolide D and ixocarpalactone A. In general, Withano

IL-1-alpha expression. IL-1-alpha is a potent stimulator of
collagenase gene expression, and its overproduction is

lides Which possess UPP-inhibitory activity have a steroid
structure With an alpha, beta-unsaturated ketone in theA ring,

Which can cause severe tissue maceration due to uncontrolled

Withanolides Were ?rst characterized as bioactive sub

observed in trauma situations such as alkali and thermal burn,

a 4-beta-hydroxy substituent, a 5,6 beta-epoxide, and a 5- or

production of stromal collagenase. Thus silencing of NF

6-member lactone substituent attached to the D ring.
The present invention also provides a method of treating a

kappaB may be a requirement for maintenance of corneal

?brotic disease, comprising administering an anti-?brotic

repair. HoWever, What signals overcome the competence to
activate NF-kappaB When corneal tissue is injured has

clarity, immune deviation and avascularity during tissue

effective amount of a Withanolide compound to a mammal in

need of treatment for ?brosis. Such ?brotic diseases include
any of the conditions enumerated above.
According to the method of the invention, one or more
Withanolide compounds can be administered to the host by an
appropriate route, either alone or in combination With another
drug. An effective amount of a Withanolide compound is

remained elusive.

administered. An effective amount is an amount suf?cient to

achieve the desired therapeutic effect, under the conditions of

20

Recently, using the keratocyte and ?broblast culture model
as representative of regenerative and ?brogenic repair mecha
nisms, respectively, Stramer et at (Invest. Ophthalmol. I/zs.
Sczl, 42(8):1698-1706, 2001) shoWed that transition to the
repair ?broblast phenotype during the 3 days after initial
plating is coincident With progressive induction of the ubiq
uitin proteasome pathWay (UPP). Levels of free ubiquitin

administration, such as an amount su?icient for inhibition of

(Ub), Ub-conjugated proteins, ubiquinylating enZymes E1

the UPP, and thereby effectively treat ?brosis.

and E2-25K, and 26S proteasome Were increased 2-5-fold in

A variety of routes of administration are possible includ

stromal cells as they transitioned from the keratocyte pheno
type into repair ?broblast phenotype. These increases Were

ing, but not necessarily limited to oral, dietary, topical,

parenteral (e.g., intravenous, intraarterial, intramuscular, sub

25

cutaneous injection), inhalation (e.g., intrabronchial, intrana
sal or oral inhalation, intranasal drops), and intraocular inj ec
tion routes of administration, depending on the disease or
condition to be treated. Intraocular injection routes include

periocular (subconjunctival/transscleral), intravitreous, sub

30

retinal and intracameral modes of injection.
Formulation of a Withanolide compound to be adminis
tered Will vary according to the route of administration

selected (e.g., solution, emulsion, capsule). An appropriate
composition comprising the Withanolide compound to be

associated With enhanced (>10-fold) capacity for Ub-depen
dent proteolysis. The levels of native I-kappa-B-alpha, but not
that of its phosphorylated form, Was elevated in activated
?broblasts compared to keratocytes, suggesting that the con

35

administered can be prepared in a physiologically acceptable
vehicle or carrier. The Withanolide compound compositions
of the invention include sustained release formulations. For
solutions or emulsions, suitable carriers include, for example,

stitutive activation of NF-kappaB promotes native I-kappa
B-alpha synthesis but, due to increased proteasome activity,
the inhibitory form (phosphorylated I-kappa-B-alpha) is rap
idly degraded. Both freshly isolated and activated ?broblasts
degraded I-kappa-B-alpha in response to IL-1-alpha; yet,
only activated ?broblasts maintained autocrine IL-1-alpha
expression after 24 hours. These authors conclude that coor
dinate induction of the UPP during ?broblast activation that

causes activated I-kappa-B-alpha to be rapidly degraded may
drive the autocrine IL-1-alpha loop, perpetuating a chronic
state of in?ammation. Since the UPP regulates NF-kappaB

pensions, including saline and buffered media. Parenteral

activation through its orchestrated degradation of I-kappa-B
alpha, the cytoplasmic inhibitor of NF -kappaB, targeting the

vehicles can include sodium chloride solution, Ringer’s dex
trose, dextrose and sodium chloride, lactated Ringer’s or

UPP may be a novel means of doWnregulating corneal ?bro
sis. The UPP has become the center of great attention because

aqueous or alcoholic/aqueous solutions, emulsions or sus

40

?xed oils. Intravenous vehicles can include various additives,

preservatives, or ?uid, nutrient or electrolyte replenishers

45

(See, generally, Remington’s Pharmaceutical Science, 16th

of its critical role in in?ammation and ?brovascular groWth,
and as an important source of multiple sites for pharmaco

logical targeting.

Edition, Mack, Ed. 1980). For inhalation, the Withanolide

The abundant corneal protein tissue transketolase (TKT) is

compound is solubiliZed and loaded into a suitable dispenser
for administration (e.g., an atomiZer, nebuliZer or pressurized

believed to play an important role in corneal homeostasis.
TKT is also a target of the UPP and its reduced expression is
believed to contribute to corneal ?brosis. In the present inven
tion, targeting the UPP in injured tissue can redirect the

aerosol dispenser).

50

Studies of Fibrosis in the Eye

?brotic repair process to acquire regenerative healing. Witha

The eye is among the organs in Which ?brosis can occur.

Tissue repair in the cornea usually occurs through a regen

erative mechanism Which helps the cornea regain its optical
function. This property has made corneal transplant surgery

nolides and related compounds, such as Withaferin A, Witha
nolide D and ixocarpalactone, are small molecule inhibitors
55

and vision corrective surgical procedures a great success.
HoWever, alkali burn injuries, severe mechanical trauma and
infectious agents can cause corneal ?brosis, and it is this

ferinA causes potent doWnregulation of UPP functions in the

alkali burn injury model of corneal angio?brotic disease.
There is also a reduction in the levels of ubiquitinated tran

impaired form of tissue repair that results in blindness. Since
the cornea can feature a regenerative or ?brotic phenotype
based on the type of injury, this tissue serves as an excellent

model to study the molecular mechanisms of ?brosis.
Corneal Wound healing is a tightly coordinated process that
must regenerate the biological and optical functions of this
refractive tissue. This process is coordinated through auto

crine and paracrine interactions of groWth factors, cytokines
and proteases produced by the stromal keratocytes, epithelial

that have potent UPP-targeting activity. Exposure to Witha

sketolase (TKT), an abundant corneal protein implicated in
60

?brogenesis.
EXAMPLE 1
The corneas of C57BL6 mice under anesthesia Were

65

injured by application of 0.1 N sodium hydroxide and subse
quently the epithelial cell layer from the cornea and limbus

Was removed by scraping. WithaferinA (WA) (2.5 mg/kg/d; 4
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mice) or vehicle (DMSO; 4 mice) Was provided daily there
after by i.p. injection for 6 d. Digital images of the corneas

in ?brotic cells. We believe that TKT is conjugated With

mono-ubiquitin species, rather than polyubiquitin species,

Were obtained to assess the extent of tissue pathology.

because the ubiquitin immunoreactivity of the 70 kDa protein

Vehicle-treated mice display profound corneal opacity and

does not smear all the Way up to the top of the gel.

Exposure of blots to X-ray ?lm for slightly longer periods

abundant groWth of neW blood vessels, Whereas in
WA-treated mice both the corneal opacity and neovascular
iZation are dramatically reduced. These compelling results
invoke the query Whether WA targets the UPP in vivo. Mice (4
per group) Were injured and treated for the ?rst 4 days With a

of time (30-40 seconds instead of 5 minutes) revealed the
presence of the TKT in WA- and epoxomicin-treated corneas,
but not in vehicle-treated mouse corneas. To investigate the

localization of TKT, immunohistochemical analysis of
mouse eyes Was conducted. TKT expression is localiZed to

different dose of WA or vehicle daily by i.p. injection. On day

the epithelium of uninjured mouse eyes, Whereas TKT
expression in corneas of 4 d vehicle-treated mice is almost

7, mice Were sacri?ced and corneal buttons Were isolated

from injured healing corneas; equal amounts of protein from
each group Were analyzed by Western blotting. Uninjured

undetectable. Staining in corneas of WA-treated mice Was

present, although at levels loWer than that of uninjured cor

felloW eyes from vehicle-treated mice served as controls.

nea, With staining being predominantly in the epithelium, and

We discovered that WA dose-dependently inhibits corneal

very little in the stroma.

expression of native l-kappa-B-alpha, Whereas expression of

This data is consistent With the general idea that ubiquiti
nated proteins are generated in the corneal epithelium upon

native l-kappa-B-alpha in vehicle-treated mice Was highly
elevated compared to uninjured corneas. We also assessed the

expression levels of HO-l, since its expression is upregulated
by angiogenic inducers during response to in?ammation. WA
potently doWnregulated HO-l expression to almost undetect

alkali burn injury as a result of oxidative damage, and removal
20

able levels as found in uninjured corneas. These ?ndings that

inhibition of l-kappa-B-alpha and HO-l expression by WA
hence corroborate the potent pharmacological activity of WA

of these damaged proteins is enabled by upregulation of the
UPP. The persistent high amount of UbTKT in injured cor
neas suggests that this protein is being retained in a posttrans
lationally-modi?ed state.
The prevailing hypothesis is that TKT plays a role in sup

25

an inhibitor of angio?brosis.

porting regenerative healing and response to environment
stress. Our ?nding that uninjured mouse corneas also express

UbTKT, although at loW levels, indicates that this variant is
physiologically removed by the UPP, and that overexpres sion
during severe tissue in?ammation promotes ?brosis. Hence,

EXAMPLE 2
30

WA Reduces Injury-Induced Expression of
Ubiguitinated Transketolase in the Cornea

TKT is a neW molecular target for anti-?brosis drug develop
ment. Moreover, WithaferinA and related Withanolides can be
used to treat ?brotic conditions
EXAMPLE 3

During tissue injury, TKT expression is doWnregulated in a

35

Anti-Fibrogenic in vivo Activity of Withaferin A

UPP-dependent manner as the tissue progresses into ?brosis.

To investigate the levels and timing of expression of TKT We

Under full anesthesia and application of topical ocular

performed time-course experiments using the angioin?am
mation corneal model of tissue repair. Groups of mice (n:0.3/
group) Were injured and treated every day With vehicle (Veh),
2.5 mg/kg/ d WA or 2.0 mg/kg/d epoxomicin (20S proteasome
inhibitor) and sacri?ced on day 4 and 6 post-in?ammation. In
a similar experiment, mice Were treated every day With
vehicle or 2.5 mg/kg/d WA and sacri?ced on days 3 and 5

anesthetic solution, a 1-mm full-thickness button of central
40

45

post-injury. Equal amounts of protein from pooled samples of

corneal tissue, including all three layers4epithelium, stroma
and endotheliumiis ablated and the area is carefully scored
by insertion and removal of a 26-gauge needle into the central
cornea employing the use of a dissecting microscope. The
full-thickness tissue button that is demarcated by the needle
insertion is removed With microdissecting scissors. After
approximately 15 minutes, a ?brin clot forms in this space,
enabling the anterior chamber to reform. The cornea is cov

each group Were subjected to immunoblotting or Coomassie

eted With erythromycin and tobramycin ophthalmic ointment

blue staining after fractionation on 4-20% gradient polyacry

to prevent infections. Atropine is administered once daily for
tWo days. The corneal tissue is harvested after 2, 5 and 8 days.
In the ?rst experiment, the dose-response of corneal ?bro
genesis to the inhibitory activity of WA in C57 BL/6J mice is
determined. The drug is freshly diluted in 1:1 salinezDMSO
and delivered by i.p. injection. Vehicle and WA at doses of 0.5,
2.0, 5 .0 and 12.0 mg/kg/d are administered for 7 or 14 days (4

lamide gels (BioRad).

50

We observed that a 70 kDa ubiquitinated protein Was abun
dantly expressed in vehicle-treated mouse corneas compared
to corneas from WA-treated mice. Coomassie blue staining,
hoWever, revealed that the levels of this protein Were not

signi?cantly altered betWeen uninjured, vehicle and

55

mice/group/time point). A second experiment is terminated
on days 3, 7, 10 and 14 (6 mice/group/time point) and

WA-treated samples at the 3- and 5-day time-points, or at the

4- and 6-day time-points examined (data not shoWn). The
Western blots of the corneal samples Were re-probed With an

employs an effective WA dose determined from experiment 1 ,

anti-mouse TKT antibody. We discovered that the uninjured
corneas expressed high levels of TKT as anticipated, but

as Well as vehicle controls.
60

surprisingly TKT from injured corneas did not bind this anti

body. Because of the strong Ub-immunoreactivity of TKT in
injured corneas, We speculate that this protein’s N-terminal

treatment groups. Digital photographic images of corneas are
also collected. These visual scores are corroborated by immu
nohistological and Western blot analyses of mouse corneas

antigenic site is being masked by ubiquitination in the injury
related samples (the TKT antibody reacts With the N-terminal
20-amino acid portion of native TKT). Our ?ndings are con
sistent With an earlier study that also failed to detect UbTKT

Mice are visually scored for corneal opacity on days 7 and
14 by employing an investigator masked to the identity of the

65

after 7 days (for 3- and 7-day treatment) and 14 days (for 10
and 14-day treatment). Three mouse corneas are employed
for Western blots and three for sectioning. The immunohisto

US 8,283,323 B2
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logical analysis includes hematoxylin-eosin staining, alpha
smooth muscle actin (marker of repair ?broblast-myo?bro
blasts), phalloidin (?lamentous actin stress ?bers), TGF
beta2 (myo?broblast-differentiation inducer), Mac-l
staining (marker of monocytes and PMNs), HO-l, l-kappa
B-alpha and ubiquitin using frozen sections. For Western

blotting, HO-l, l-kappa-B-alpha, ubiquitin, TKT, alpha
smooth muscle (sm) actin and TGF-beta2 expression are ana

lyZed.
All references cited in this disclosure are incorporated by
reference to the same extent as if each reference had been

incorporated by reference in its entirety individually.
While the invention has been described in detail and With

reference to speci?c embodiments thereof, it Will be apparent
to one skilled in the art that various variations and modi?ca

tions can be made therein Without departing from the sprit and
scope thereof. All such variations and modi?cations are
intended to be included Within the scope of this disclosure and

the present invention and protected by the folloWing claims.

8
We claim:
1. A method of treating a ?brotic disease in a mammal
comprising administering an anti-?brotic effective amount of
a Withanolide compound to a mammal in need of treatment

for ?brosis of the eye Wherein the anti-?brotic effective
amount is 0.5 to 12 mg/kg/day.
2. The method of claim 1 Wherein the Withanolide com

pound is Withthaferin A.
3. The method of claim 1 Wherein the Withanolide com

pound is Withthanolide D.
4. The method of claim 1 Wherein the Withanolide com

pound is ixocarpalactone A.
5. The method of claim 1 Wherein the Withanolide com

pound is orally administered to the mammal.
6. The method of claim 1 Wherein the Withanolide com

pound is intravenously administered to the mammal.
7. The method of claim 1 Wherein the Withanolide com

pound is intraocularly injected into the mammal.
*

*

*

*
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